Citadel Advisors
ACRS icon

Citadel Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Citadel Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$384K Buy
+102,300
New +$345K ﹤0.01% 9901
2025
Q2 		– Sell
-32,000
Closed -$49K – 12324
2025
Q1 		$49K Sell
32,000
-700
-2% -$1.49K ﹤0.01% 12331
2024
Q4 		$81.1K Buy
32,700
+31,700
+3,170% +$78.9K ﹤0.01% 11768
2024
Q3 		$1.15K Sell
1,000
-2,300
-70% -$2.82K ﹤0.01% 13892
2024
Q2 		$3.63K Sell
3,300
-12,600
-79% -$14.8K ﹤0.01% 13571
2024
Q1 		$19.7K Sell
15,900
-17,600
-53% -$21K ﹤0.01% 13024
2023
Q4 		$35.2K Sell
33,500
-74,800
-69% -$228K ﹤0.01% 12127
2023
Q3 		$742K Buy
108,300
+21,900
+25% +$187K ﹤0.01% 7222
2023
Q2 		$896K Sell
86,400
-49,600
-36% -$449K ﹤0.01% 6688
2023
Q1 		$1.1M Buy
136,000
+132,900
+4,287% +$1.69M ﹤0.01% 6559
2022
Q4 		$48.8K Buy
+3,100
New +$49.9K ﹤0.01% 12173
2021
Q4 		– Sell
-22,900
Closed -$412K – 13699
2021
Q3 		$412K Buy
22,900
+12,500
+120% +$200K ﹤0.01% 10337
2021
Q2 		$183K Sell
10,400
-21,600
-68% -$491K ﹤0.01% 12260
2021
Q1 		$806K Buy
32,000
+17,700
+124% +$346K ﹤0.01% 8624
2020
Q4 		$93K Buy
+14,300
New +$60.3K ﹤0.01% 10266

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's ACRS Position: Q1 2026 in Review

Citadel Advisors increased its Aclaris Therapeutics (ACRS) stake by 87% in Q1 2026, buying an estimated $3.52M and bringing the position to 2,249,319 shares worth $8.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3488.

Citadel Advisors first reported a position in ACRS in Q3 2016 and has held it in 37 quarters since. The position peaked at $33.4M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Citadel Advisors held 2,249,319 shares of Aclaris Therapeutics worth $8.43M as of Q1 2026.
  • Citadel Advisors bought 1,044,038 Aclaris Therapeutics shares in Q1 2026, an estimated $3.52M.
  • Aclaris Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3488 holding.
  • Citadel Advisors first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 37 quarters since.
  • Citadel Advisors's Aclaris Therapeutics position peaked at $33.4M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.